back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2019-10-30 16:20 Tx date 2019-10-30 |
$RQB
RavenQuest BioMed Inc. |
Ahrens-Townsend, Mark William
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-10-30 16:19 Tx date 2019-10-30 |
$RQB
RavenQuest BioMed Inc. |
Ahrens-Townsend, Mark William
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-10-30 16:19 Tx date 2019-10-30 |
$RQB
RavenQuest BioMed Inc. |
Ahrens-Townsend, Mark William
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
165,000 | ||
| Filed 2018-06-01 Tx date 2018-06-01 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$40,000
+200,000 vol $0.20 each |
889,000 | |
| Filed 2018-03-27 Tx date 2018-03-27 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,900
+20,000 vol $0.095 each |
1,294,500 | |
| Filed 2018-03-12 Tx date 2018-03-09 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,550
+74,000 vol $0.075 each |
1,274,500 | |
| Filed 2018-01-05 Tx date 2018-01-05 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,500
+100,000 vol $0.085 each |
1,200,500 | |
| Filed 2017-12-20 Tx date 2017-12-14 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$50.00
+500 vol $0.10 each |
1,100,500 | |
| Filed 2017-08-17 Tx date 2017-08-17 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+250,000 vol |
500,000 | |
| Filed 2017-08-17 Tx date 2017-08-17 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$30,000
+250,000 vol $0.12 each |
1,100,000 | |
| Filed 2017-08-01 Tx date 2017-07-24 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$48,000
+160,000 vol $0.30 each |
689,000 | |
| Filed 2017-07-20 Tx date 2017-07-14 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
$45,000
+250,000 vol $0.18 each |
250,000 | |
| Filed 2017-07-20 Tx date 2017-07-14 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$30,000
+250,000 vol $0.12 each |
850,000 | |
| Filed 2017-07-20 Tx date 2015-05-11 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-03-13 Tx date 2017-03-13 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-2,400,000 vol |
600,000 | |
| Filed 2017-03-13 Tx date 2017-03-13 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-2,116,000 vol |
529,000 | |
| Filed 2016-11-14 Tx date 2016-05-03 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Rights
57 - Exercise of rights
|
$-39,150
-1,305,000 vol $0.03 each |
0 | |
| Filed 2016-11-14 Tx date 2016-04-05 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Rights
56 - Grant of rights
|
+1,305,000 vol |
||
| Filed 2016-11-14 Tx date 2016-04-05 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Rights
56 - Grant of rights
|
$39,150
+1,305,000 vol $0.03 each |
1,305,000 | |
| Filed 2016-11-14 Tx date 2016-05-03 |
$KNE
Kane Biotech Inc. |
Ahrens-Townsend, Mark William
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Rights
57 - Exercise of rights
|
-1,305,000 vol |